XML 51 R35.htm IDEA: XBRL DOCUMENT
v3.25.3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Accounting Policies [Abstract] |
Schedule of Cash and Cash Equivalents | Cash, cash equivalents and restricted cash consist of the following:
| March 31, 2025 |  | December 31, 2024
Cash and cash equivalents | $ | 138,303 |  |  | $ | 146,852 |
Restricted cash | 1,375 |  |  | 100,475 |
Total cash, cash equivalents and restricted cash | $ | 139,678 |  |  | $ | 247,327 |
Schedule of Restrictions on Cash and Cash Equivalents | Cash, cash equivalents and restricted cash consist of the following:
| March 31, 2025 |  | December 31, 2024
Cash and cash equivalents | $ | 138,303 |  |  | $ | 146,852 |
Restricted cash | 1,375 |  |  | 100,475 |
Total cash, cash equivalents and restricted cash | $ | 139,678 |  |  | $ | 247,327 |
Schedule of Securities and Other Investments Owned and Securities Sold not Yet Purchased at Fair Value | The Company’s securities and other investments owned and securities sold not yet purchased consisted of the following as of March 31, 2025 and December 31, 2024:
| March 31, 2025 |  | December 31, 2024
Securities and other investments owned: |  |  |
Securities and other investments owned at fair value: |  |  |
Equity securities | $ | 107,200 |  |  | $ | 165,408 |
Corporate bonds | 30,808 |  |  | 29,027 |
Other fixed income securities | 2,390 |  |  | 4,923 |
Partnership interests and other | 21,145 |  |  | 15,867 |
Total securities and other investments owned at fair value: | 161,543 |  |  | 215,225 |
Equity securities valued under the measurement alternative | 70,217 |  |  | 67,100 |
Total securities and other investments owned | $ | 231,760 |  |  | $ | 282,325 |
Securities sold not yet purchased: |  |  |
Equity securities | $ | 548 |  |  | $ | — |
Corporate bonds | 840 |  |  | 1,891 |
Other fixed income securities | 752 |  |  | 3,784 |
Total securities sold not yet purchased | $ | 2,140 |  |  | $ | 5,675 |
Schedule of Equity Securities Without Readily Determinable Fair Value | The following table presents, as of March 31, 2025 and December 31, 2024, the carrying value of equity securities measured under the measurement alternative investments and the related adjustments recorded during the periods presented for those securities with observable price changes:
| March 31, 2025 |  | December 31, 2024
Securities and other investments owned, carrying value | $ | 70,217 |  |  | $ | 67,100 |
Upward carrying value changes | 1,732 |  |  | 1,848 |
Downward carrying value changes/impairment | (592) |  |  | (2) |
Schedule of Financial Assets Measured on Nonrecurring Basis | The following table presents information on equity securities valued under the measurement alternative on a nonrecurring basis by level within the fair value hierarchy which were measured due to an observable price change or impairment during the periods below.
| Total |  | Quoted prices in active markets for identical assets (Level 1) |  | Other observable inputs (Level 2) |  | Significant unobservable inputs (Level 3)
As of March 31, 2025 |  |  |  |  |  |  |
Equity securities valued under the measurement alternative | $ | 12,101 |  |  | $ | — |  |  | $ | 10,843 |  |  | $ | 1,258 |
As of December 31, 2024 |  |  |  |  |  |  |
Equity securities valued under the measurement alternative | $ | 7,294 |  |  | $ | — |  |  | $ | 7,294 |  |  | $ | — |
Schedule of Equity Method Investments | The following tables contain summarized financial information with respect to Freedom VCM, included below for purposes of the disclosure a quarter in arrears (consolidated balance sheet amounts as of September 30, 2024 correspond to amounts as of December 31, 2024 of the Company; income statement amounts during the three months ended December 31, 2023 correspond to amounts for the three months ended March 31, 2024 of the Company), which is the period in which the most recent financial information was available.
|  | September 30, 2024
Current assets |  | $ | 871,102 |
Noncurrent assets |  | $ | 2,889,334 |
Current liabilities |  | $ | 569,281 |
Noncurrent liabilities |  | $ | 2,680,178 |
Equity attributable to investee |  | $ | 510,977 |
|  | Three Months Ended December 31, 2023
Revenues |  | $ | 806,229 |
Cost of revenues |  | $ | 499,679 |
Loss from continuing operations |  | $ | (1,175) |
Net loss attributable to investees |  | $ | (169,583) |
The following tables contain summarized financial information with respect to B&W included below for purposes of the disclosure a quarter in arrears (balance sheet amounts as of December 31, 2024 and September 30, 2024 correspond to amounts as of March 31, 2025 and December 31, 2024, respectively, of the Company; income statement amounts during the three months ended December 31, 2024 and 2023 correspond to amounts during the three months ended March 31, 2025 and 2024, respectively, of the Company), which is the period in which the most recent financial information is available:
| December 31, 2024 |  | September 30, 2024
Current assets | $ | 490,185 |  |  | $ | 530,223 |
Noncurrent assets | $ | 236,802 |  |  | $ | 274,410 |
Current liabilities | $ | 388,493 |  |  | $ | 297,928 |
Noncurrent liabilities | $ | 621,666 |  |  | $ | 709,823 |
Deficit attributable to investee | $ | (283,763) |  |  | $ | (203,694) |
Noncontrolling interest | $ | 591 |  |  | $ | 576 |
|  |  | For the Three Months Ended December 31,
|  |  |  |  | 2024 |  | 2023
Revenues |  |  |  |  | $ | 66,276 |  |  | $ | 227,167 |
Cost of revenues |  |  |  |  | $ | 42,043 |  |  | $ | 171,552 |
Loss from continuing operations |  |  |  |  | $ | (71,318) |  |  | $ | (54,266) |
Net loss |  |  |  |  | $ | (63,021) |  |  | $ | (62,724) |
Net loss attributable to investees |  |  |  |  | $ | (63,065) |  |  | $ | (66,454) |
The following summarized income statement for Synchronoss Technologies, Inc. is included below for purposes of disclosure a quarter in arrears whereas the three months ended December 31, 2023 correspond to amounts during the three months ended March 31, 2024 of the Company, which was the period in which the most recent financial information was available:
|  | Three Months Ended December 31, 2023
Revenues |  | $ | 41,402 |
Cost of revenues |  | $ | 10,292 |
Net loss attributable to investees |  | $ | (35,001) |
The following table contains summarized financial information for these companies, included below for purposes of the disclosure a quarter in arrears (balance sheet amounts as of December 31, 2024 and September 30, 2024 correspond to amounts as of March 31, 2025 and December 31, 2024, respectively, of the Company; income statement amounts during the three months ended December 31, 2024 and 2023 correspond to amounts during the three months ended March 31, 2025 and 2024, respectively, of the Company), which is the period in which the most recent financial information is available:
| December 31, 2024 |  | September 30, 2024
Current assets | $ | 20,552 |  |  | $ | 215,927 |
Noncurrent assets | $ | 119,695 |  |  | $ | 572,628 |
Current liabilities | $ | 9,827 |  |  | $ | 86,672 |
Noncurrent liabilities | $ | 69,309 |  |  | $ | 105,711 |
Equity attributable to investee | $ | 61,111 |  |  | $ | 596,172 |
|  |  | For the Three Months Ended December 31,
|  |  |  |  | 2024 |  | 2023
Revenues |  |  |  |  | $ | 11,723 |  |  | $ | 145,974 |
Cost of revenues |  |  |  |  | $ | 2,794 |  |  | $ | 127,348 |
Net loss attributable to investees |  |  |  |  | $ | (2,314) |  |  | $ | (10,505) |
The following tables contain summarized financial information with respect to GA Holdings, included below for purposes of the disclosure a quarter in arrears (balance sheet amounts as of December 31, 2024 correspond to amounts as of March 31, 2025 and income statement amounts during the period from November 15, 2024 to December 31, 2024 correspond to amounts for the quarter ended March 31, 2025):
|  | December 31, 2024
Current assets |  | $ | 34,922 |
Noncurrent assets |  | $ | 291,362 |
Current liabilities |  | $ | 34,735 |
Mezzanine equity - preferred units |  | $ | 279,096 |
Equity attributable to investee |  | $ | 12,453 |
|  | Period From
|  | November 15, 2024 to
|  | December 31, 2024
Revenue |  | $ | 21,675 |
Cost of revenue and expenses |  | $ | 18,184 |
Net income attributable to investee |  | $ | 3,490 |
Schedule of Financial Assets and Liabilities Measured on Recurring Basis | The following tables present information on the financial assets and liabilities measured and recorded at fair value on a recurring basis as of March 31, 2025 and December 31, 2024.
| Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis as of March 31, 2025 Using
| Fair value as of March 31, 2025 |  | Quoted prices in active markets for identical assets (Level 1) |  | Other observable inputs (Level 2) |  | Significant unobservable inputs (Level 3)
Assets: |  |  |  |  |  |  |
Securities and other investments owned: |  |  |  |  |  |  |
Equity securities | $ | 107,200 |  |  | $ | 79,670 |  |  | $ | — |  |  | $ | 27,530 |
Corporate bonds | 30,808 |  |  | 536 |  |  | 30,272 |  |  | — |
Other fixed income securities | 2,390 |  |  | — |  |  | 2,390 |  |  | — |
Total securities and other investments owned | 140,398 |  |  | 80,206 |  |  | 32,662 |  |  | 27,530 |
Loans receivable, at fair value | 98,596 |  |  | — |  |  | — |  |  | 98,596 |
Total assets measured at fair value | $ | 238,994 |  |  | $ | 80,206 |  |  | $ | 32,662 |  |  | $ | 126,126 |
Liabilities: |  |  |  |  |  |  |
Securities sold not yet purchased: |  |  |  |  |  |  |
Equity securities | $ | 548 |  |  | $ | 548 |  |  | $ | — |  |  | $ | — |
Corporate bonds | 840 |  |  | 1 |  |  | 839 |  |  | — |
Other fixed income securities | 752 |  |  | — |  |  | 752 |  |  | — |
Total securities sold not yet purchased | 2,140 |  |  | 549 |  |  | 1,591 |  |  | — |
Contingent consideration | 4,593 |  |  | — |  |  | — |  |  | 4,593 |
Liability-classified warrants | 5,160 |  |  | — |  |  | — |  |  | 5,160 |
Embedded derivative | 14,593 |  |  | — |  |  | — |  |  | 14,593 |
Total liabilities measured at fair value | $ | 26,486 |  |  | $ | 549 |  |  | $ | 1,591 |  |  | $ | 24,346 |
| Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis at December 31, 2024 Using
| Fair value at December 31, 2024 |  | Quoted prices in active markets for identical assets (Level 1) |  | Other observable inputs (Level 2) |  | Significant unobservable inputs (Level 3)
Assets: |  |  |  |  |  |  |
Securities and other investments owned: |  |  |  |  |  |  |
Equity securities | $ | 165,408 |  |  | $ | 124,892 |  |  | $ | — |  |  | $ | 40,516 |
Corporate bonds | 29,027 |  |  | 25,461 |  |  | 3,566 |  |  | — |
Other fixed income securities | 4,923 |  |  | — |  |  | 4,923 |  |  | — |
Total securities and other investments owned | 199,358 |  |  | 150,353 |  |  | 8,489 |  |  | 40,516 |
Loans receivable, at fair value | 90,103 |  |  | — |  |  | — |  |  | 90,103 |
Total assets measured at fair value | $ | 289,461 |  |  | $ | 150,353 |  |  | $ | 8,489 |  |  | $ | 130,619 |
Liabilities: |  |  |  |  |  |  |
Securities sold not yet purchased: |  |  |  |  |  |  |
Corporate bonds | $ | 1,891 |  |  | $ | — |  |  | $ | 1,891 |  |  | $ | — |
Other fixed income securities | 3,784 |  |  | — |  |  | 3,784 |  |  | — |
Total securities sold not yet purchased | 5,675 |  |  | — |  |  | 5,675 |  |  | — |
Contingent consideration | 4,538 |  |  | — |  |  | — |  |  | 4,538 |
Total liabilities measured at fair value | $ | 10,213 |  |  | $ | — |  |  | $ | 5,675 |  |  | $ | 4,538 |
Schedule of Fair Value Measurement Inputs and Valuation Techniques | The following table summarizes the significant unobservable inputs in the fair value measurement of Level 3 financial assets and liabilities by category of investment and valuation technique as of March 31, 2025 and December 31, 2024:
| Fair value at March 31, 2025 |  | Valuation Technique |  | Unobservable Input |  | Range |  | Weighted Average(1)
Assets: |  |  |  |  |  |  |  |  |
Equity securities | $ | 22,656 |  |  | Market approach |  | Multiple of EBITDA(2) |  | 5.5x |  | 5.5x
|  |  |  |  | Multiple of Sales |  | 1.9x - 6.0x |  | 2.7x
|  |  |  |  | Market price of related security |  | $10.22 - $11.72 |  | $11.21
| 4,874 |  |  | Option pricing model |  | Annualized volatility |  | 47.0% - 175.0% |  | 64.0%
Loans receivable at fair value | 77,687 |  |  | Discounted cash flow |  | Discount rate |  | 7.7% - 22.8% |  | 19.8%
| 15,000 |  |  | Liquidation approach |  | Cash recovery rate |  | 16.1% |  | 16.1%
| 5,909 |  |  | Market approach |  | Market price of related security |  | $10.89 |  | $10.89
Total level 3 assets measured at fair value | $ | 126,126 |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration | $ | 4,593 |  |  | Discounted cash flow |  | Discount rate |  | 5.0% - 7.5% |  | 5.1%
Liability-classified warrants | 5,160 |  |  | Monte Carlo simulation and Black-Scholes option pricing model |  | Annualized volatility |  | 75.0% |  | 75.0%
|  |  |  |  | Discount for lack of marketability |  | 13.7% |  | 13.7%
Embedded derivative | 14,593 |  |  | Discounted cash flow |  | Discount rate |  | 24.3% |  | 24.3%
|  |  | Monte Carlo simulation model |  | Annualized volatility |  | 105.0% |  | 105.0%
|  |  |  |  | Expected term |  | 2.9 years |  | 2.9 years
Total level 3 liabilities measured at fair value | $ | 24,346 |  |  |  |  |  |  |  |  |
(1) Unobservable inputs were weighted by the relative fair value of the financial instruments. (2) Multiple of earnings before interest, taxes, depreciation, and amortization ("EBITDA").
| Fair value at December 31, 2024 |  | Valuation Technique |  | Unobservable Input |  | Range |  | Weighted Average(1)
Assets: |  |  |  |  |  |  |  |  |
Equity securities | $ | 34,654 |  |  | Market approach |  | Multiple of EBITDA |  | 6.3x |  | 6.3x
|  |  |  |  | Multiple of Sales |  | 2.1x - 8.0x |  | 3.1x
|  |  |  |  | Market price of related security |  | $9.97 - $11.10 |  | $10.76
| 5,862 |  |  | Option pricing model |  | Annualized volatility |  | 47.0% - 171.0% |  | 87.0%
Loans receivable at fair value | 86,150 |  |  | Discounted cash flow |  | Discount rate |  | 7.3% - 69.1% |  | 19.7%
| 3,953 |  |  | Market approach |  | Market price of related security |  | $9.60 - $16.48 |  | $12.90
Total level 3 assets measured at fair value | $ | 130,619 |  |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |
Contingent consideration | 4,538 |  |  | Discounted cash flow |  | Discount rate |  | 5.0% - 7.5% |  | 5.1%
Total level 3 liabilities measured at fair value | $ | 4,538 |  |  |  |  |  |  |  |  |
(1) Unobservable inputs were weighted by the relative fair value of the financial instruments. The table below summarizes the significant unobservable inputs in determining the fair value measurement on a nonrecurring basis of the noncontrolling interest issued on March 10, 2025 as described above. In determining the fair value below the valuation utilized a weighting of 75% for the discounted cash flow method and 25% for the market approach.
| Fair Value at Measurement Date |  | Valuation Technique |  | Unobservable Input |  | Range |  | Weighted Average
Nonrecurring |  |  |  |  |  |  |  |  |
Noncontrolling interest | $ | 1,575 |  |  | Discounted cash flow and market approach |  | Market interest rate and multiple of EBIT |  | Discount rate 21% and multiple of EBIT 5.75x-10.00x |  | Discount rate 21% and multiple of EBIT 7.3x(1)
(1) Unobservable inputs were weighted by the relative equity value of BRSH.
Schedule of Fair Value Measurement of Level 3 Financial Assets and Liabilities | The changes in Level 3 fair value hierarchy during the three months ended March 31, 2025 and 2024 were as follows:
| Level 3 Balance at Beginning of Year |  | Level 3 Changes During the Period |  |  |  | Level 3 Balance at End of Period |  | Change in unrealized gains (losses) (2)
| Fair Value Adjustments (1) |  | Relating to Undistributed Earnings |  | Purchases/ Originations |  | Sales |  | Settlements/ Repayments |  | Transfer in and/or out of Level 3 |  |
Three Months Ended March 31, 2025 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity securities | $ | 40,516 |  |  | $ | (3,844) |  |  | $ | — |  |  | $ | 869 |  |  | $ | (10,000) |  |  | $ | (11) |  |  | $ | — |  |  | $ | 27,530 |  |  | $ | (3,844) |
Loans receivable at fair value | 90,103 |  |  | (8,096) |  |  | — |  |  | 58,008 |  |  | (6,840) |  |  | (34,579) |  |  | — |  |  | 98,596 |  |  | (9,738) |
Contingent consideration | 4,538 |  |  | 103 |  |  | — |  |  | — |  |  | — |  |  | (48) |  |  | — |  |  | 4,593 |  |  | (103) |
Liability-classified warrants | — |  |  | (2,700) |  |  | — |  |  | 7,860 |  |  | — |  |  | — |  |  | — |  |  | 5,160 |  |  | 2,700 |
Embedded derivative | — |  |  | 3,349 |  |  | — |  |  | 11,244 |  |  | — |  |  | — |  |  | — |  |  | 14,593 |  |  | (3,349) |
Three Months Ended March 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity securities | $ | 452,581 |  |  | $ | (56,388) |  |  | $ | 12 |  |  | $ | 435 |  |  | $ | (9,322) |  |  | $ | — |  |  | $ | (1,074) |  |  | $ | 386,244 |  |  | $ | (57,197) |
Loans receivable at fair value | 532,419 |  |  | (12,130) |  |  | 3,089 |  |  | 30,976 |  |  | (22,785) |  |  | (79,073) |  |  | — |  |  | 452,496 |  |  | (20,812) |
Contingent consideration | 25,194 |  |  | (148) |  |  | — |  |  | — |  |  | — |  |  | (70) |  |  | — |  |  | 24,976 |  |  | 148 |
(1) Fair value adjustments during the three months ended March 31, 2025 includes the following: $(3,844) of realized and unrealized gains (losses) on equity securities comprised of $(1,082) included in "Trading gains (losses), net" and $(2,762) included in "Realized and unrealized losses on investments", $(8,096) of fair value adjustments on loans included in "Fair value adjustments on loans", $(103) of realized and unrealized losses related to contingent consideration included in "Selling, general and administrative expenses", $2,700 of unrealized gains related to liability-classified warrants included in "Change in fair value of financial instruments and other", and $(3,349) of unrealized losses related to embedded derivatives included in "Change in fair value of financial instruments and other" line items in the unaudited condensed consolidated statements of operations. Fair value adjustments during the three months ended March 31, 2024 includes the following: $(56,388) of realized and unrealized gains (losses) on equity securities is comprised of $(10,390) relating to equity securities included in "Trading gains (losses), net" and $(45,998) of realized and unrealized gains (losses) included in "Realized and unrealized losses on investments", $(12,130) of fair value adjustments on loans included in "Fair value adjustments on loans", and $(148) related to contingent consideration included in "Selling, general and administrative expenses" line items in the unaudited condensed consolidated statements of operations. (2) For the three months ended March 31, 2025 and 2024, the change in unrealized gains (losses) is related to financial instruments held at the end of each respective reporting period.
Schedule of Investments in the VIE | The carrying amounts included in the Company’s unaudited condensed consolidated balance sheets related to variable interests in VIEs that were not consolidated is shown below.
| March 31, 2025 |  | December 31, 2024
Securities and other investments owned, at fair value | $ | 6,163 |  |  | $ | — |
Loans receivable, at fair value | 34,094 |  |  | 28,193 |
Other assets | 3,801 |  |  | 3,359 |
Maximum exposure to loss | $ | 44,058 |  |  | $ | 31,552 |
The carrying amounts and classification of the assets, liabilities and noncontrolling interest of the BRC Trust as of March 31, 2025 and formation on January 6, 2025, are as follows:
| March 31, 2025 |  | January 6, 2025
Assets |  |  |
Cash and cash equivalents | $ | 744 |  |  | $ | 359 |
Securities and other investments owned, at fair value | 577 |  |  | 577 |
Loans receivable, at fair value | 3,575 |  |  | 10,276 |
Prepaid expenses and other assets | 3,824 |  |  | 3,497 |
Total assets | $ | 8,720 |  |  | $ | 14,709 |
Liabilities |  |  |
Accrued expenses and other liabilities | $ | 528 |  |  | $ | 290 |
Total liabilities | $ | 528 |  |  | $ | 290 |
Noncontrolling interest | $ | 7,099 |  |  | $ | 12,494 |

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of cash and cash equivalents. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 8 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details
Name: | us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of financial instruments held by a broker-dealer for its own account (proprietary securities) for trading or investment purposes that are carried at fair value including securities sold, not yet purchased. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContent + Details
Name: | us-gaap_ScheduleOfSecuritiesOwnedAndSoldNotYetPurchasedAtFairValueTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-9 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-6 + Details
Name: | us-gaap_ScheduleOfVariableInterestEntitiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration